Abstract: A fluid manifold for distributing a source of fluid is described, and which includes a valve body having a plurality of fluid outlets which are coupled in fluid receiving communication relative to an internal cavity, and which is defined by the valve body, and a selectively adjustable valve member is received within the internal cavity of the valve body, and is further operable to meter the source of fluid delivered into the internal cavity and which then escapes the valve body by way of the plurality of fluid outlets for distribution to a predetermined destination.

Abstract: A safety helmet includes an outer collapsible shell that collapses toward an inner shell when an impact force is received, and does not return toward its initial (pre-collapsed) state when the impact force is removed. The safety helmet provides improved protection against injuries.

Abstract: Provided are methods and compositions for reducing airway hyperresponsiveness and other inflammatory diseases, disorders and conditions in a mammal by decreasing FIZZ1 (Found in Inflammatory Zone 1) activity. Also provided are methods and compositions for identifying modulators of airway inflammation and/or inhibitors of FIZZ1. The present invention encompasses modulators of airway inflammation and/or inhibitors of FIZZ1 and uses thereof. In addition, the present invention provides methods and compositions for enhancing an immune response based on FIZZ1 protein.

Abstract: The present invention provides compositions and methods useful for detecting or treating asthma or other allergic or inflammatory diseases. In one aspect, the methods of the present invention include inhibiting the activity or expression of a component of an arginine metabolic pathway in tissues affected by asthma or other allergic or inflammatory diseases. In many embodiments, the component being inhibited is a cationic amino acid transporter, an arginase, or a component downstream of the arginase. In many other embodiments, the activity or expression of the component is inhibited by an agent that binds to the component. In still many other embodiments, the activity or expression of the component is inhibited by an agent that binds a polynucleotide encoding the component.

Abstract: Polynucleotides encoding novel proteases designated “FMH-1” are disclosed. Host cells transformed with such polynucleotides and methods for making FMH-1 proteases are also disclosed. The invention also provides FMH-1 proteases and antibodies that react with them, along with pharmaceutical compositions comprising FMH-1 proteases or polynucleotides encoding FMH-1 proteases. Methods for treating conditions associated with excessive or insufficient apoptosis by administering such pharmaceutical compositions are also disclosed.

Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.

Abstract: The present invention provides compositions and methods useful for detecting or treating asthma or other allergic or inflammatory diseases. In one aspect, the methods of the present invention include inhibiting the activity or expression of a component of an arginine metabolic pathway in tissues affected by asthma or other allergic or inflammatory diseases. In many embodiments, the component being inhibited is a cationic amino acid transporter, an arginase, or a component downstream of the arginase. In many other embodiments, the activity or expression of the component is inhibited by an agent that binds to the component. In still many other embodiments, the activity or expression of the component is inhibited by an agent that binds a polynucleotide encoding the component.

Abstract: Polynucleotides encoding novel proteases designated “FMH-1” are disclosed.

Abstract: Polynucleotides encoding novel proteases designated “FMH-1” are disclosed. Host cells transformed with such polynucleotides and methods for making FMH-1 proteases are also disclosed. The invention also provides FMH-1 proteases and antibodies that react with them, along with pharmaceutical compositions comprising FMH-1 proteases or polynucleotides encoding FMH-1 proteases. Methods for treating conditions associated with excessive or insufficient apoptosis by administering such pharmaceutical compositions are also disclosed.

Abstract: Isolated polynucleotides which have been derived from a variety of human tissue sources, and which encode novel secreted proteins, are provided. Also provided are methods for producing proteins using these polynucleotides, and the proteins so produced.

Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.

Abstract: A novel secreted and glycophosphatidylinositol-anchored protein, GPI-122, is disclosed, as are antibodies that specifically bind to this protein. Polynucleotides encoding GPI-122 are also provided.

Abstract: Novel EBI-3-alt polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length EBI-3-alt proteins, the invention further provides isolated EBI-3-alt fusion proteins, antigenic peptides and anti-EBI-3-alt antibodies. The invention also provides EBI-3-alt nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an EBI-3-alt gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: Polynucleotides encoding novel proteases designated “FMH-1” are disclosed.